Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases

Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR‐tyrosine kinase inhibitors (TKIs) as standard‐of‐care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M‐resistant mutations are the most common, and osimertinib has been fo...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Respirol Case Rep
Prif Awduron: Takeda, Takayuki, Itano, Hideki, Takeuchi, Mayumi, Nishimi, Yurika, Saitoh, Masahiko, Takeda, Sorou
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Ltd 2017
Pynciau:
Case Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412970/
https://ncbi.nlm.nih.gov/pubmed/28469919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.241
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg